Right to Try Clarification Act

Senate Bill 4575 - Right to Try Clarification Act: Overview, Status, and Impact

Hozzl · 2022-12-29T18:48:40Z

Explore the details of Senate Bill 4575 Right to Try Clarification Act currently in Congress. Get insights into its purpose, current status, sponsors, and potential impact on Health. Stay informed on legislative developments.

12/29/2022, 6:48 PM

Congressional Summary of S 4575

Right to Try Clarification Act

This bill specifies that investigational drugs that are provided directly to individuals from manufacturers without the need for federal regulatory approval (i.e., via the Right to Try pathway) are exempt from restrictions that would otherwise apply under the Controlled Substances Act (e.g., restrictions on the use or possession of schedule I controlled substances).

Read the Full Bill

Formatted Text PDF Formatted XML

Current Status of Bill S 4575

Bill S 4575 is currently in the status of Bill Introduced since July 20, 2022. Bill S 4575 was introduced during Congress 117 and was introduced to the Senate on July 20, 2022. Bill S 4575's most recent activity was Read twice and referred to the Committee on the Judiciary. as of July 20, 2022

Bipartisan Support of Bill S 4575

Total Number of Sponsors

Democrat Sponsors

Republican Sponsors

Unaffiliated Sponsors

Total Number of Cosponsors

Democrat Cosponsors

Republican Cosponsors

Unaffiliated Cosponsors

Policy Area and Potential Impact of Bill S 4575

Primary Policy Focus

Health

Alternate Title(s) of Bill S 4575

Right to Try Clarification Act

A bill to clarify that the Federal Right to Try law applies to schedule I substances for which a phase I clinical trial has been completed and to provide access for eligible patients to such substances pursuant to the Federal Right to Try law.